Each year approximately 63,000 persons in the US will be diagnosed with thyroid cancer, placing it among the top 10 most common cancers in the country.
Keith C. Bible, MD, PhD, professor of oncology, Mayo Clinic, discusses the challenges associated with treating patients with follicular cell-derived thyroid carcinoma.
Over the past few decades, the annual incidence of OPSCC has increased sharply in several countries, including in the United States.
Lily Kwatampora, MD, discusses the relationship between body composition and targeted therapies in patients with thyroid cancer.
More breast cancer lesions were diagnosed in women with dense breasts when ultrasound screening was conducted in conjunction with mammography compared with mammography alone.
An international team of investigators is evaluating the novel topoisomerase-1 inhibitor etirinotecan pegol in patients with metastatic breast cancer, and at the same time evaluating target-specific biomarkers in CTCs.
A potential pathogenic role for the androgen receptor (AR) exists for some breast cancer (BC) subtypes according to 2 new studies presented at the San Antonio Breast Cancer Symposium (SABCS) 2014.
JTT Articles
Dacomitinib Shows Responses in Subset of Head and Neck Cancer
Bromodomain Inhibitor Shows Activity in Hematologic Malignancies
CD19-Targeted Agents Continue to Show Positive Outcomes
External Resources

AJMC
Cure
HCPLive
OncLive
PainLive
Pharmacy Times
Physicians' Education Resource
Physician's Money Digest
Internal Resources

Articles
Fellows
Publications
Targeted Communications
Resources
Connect With Us:

About Us
Advertise
Contact Us
Privacy Policy
Terms & Conditions
Intellisphere, LLC
666 Plainsboro Road
Building 300
Plainsboro, NJ 08536
P: 609-716-7777
F: 609-716-4747

Copyright TargetedOnc 2013
Intellisphere, LLC. All Rights Reserved.